Treatment of Hypertension in Chronic Kidney Disease

Introduction to Hypertension Management

• The American College of Cardiology recommends that all patients with CKD and hypertension should receive an ACE inhibitor or ARB as first-line therapy, with a blood pressure goal of less than 130/80 mmHg 1, 2, 3

Blood Pressure Targets

• Target BP should be <130/80 mmHg for all adults with CKD and hypertension 1, 2, 3
• For patients with moderate-to-severe CKD (eGFR >30 mL/min/1.73 m²), aim for a systolic BP of 120-129 mmHg if tolerated, as this provides additional cardiovascular and renal protection 1, 2, 3
• These targets are more aggressive than older JNC-8 guidelines which recommended <140/90 mmHg, reflecting newer evidence showing benefit from tighter control 4, 5

First-Line Medication Selection

• ACE inhibitors are the preferred first-line agent for all CKD patients with hypertension 1, 2, 3
• ACE inhibitors (or ARBs if ACE inhibitors are not tolerated) are strongly recommended for CKD stage 3 or higher regardless of albuminuria 1
• ACE inhibitors (or ARBs if ACE inhibitors are not tolerated) are strongly recommended for CKD stage 1-2 with any degree of albuminuria 1, 2
• Administer ACE inhibitors or ARBs at the highest approved dose that is tolerated to achieve maximum renoprotective benefits 2

Monitoring After Initiation

• Check blood pressure, serum creatinine, and serum potassium within 2-4 weeks of starting or increasing the dose of an ACE inhibitor or ARB 2, 3
• Continue the ACE inhibitor or ARB unless serum creatinine rises by more than 30% within 4 weeks of initiation or dose increase 2, 3

Add-On Therapy When BP Goal Not Achieved

• Second-line: Add either a long-acting dihydropyridine calcium channel blocker OR a thiazide-type diuretic 3
• Third-line: Add the other class not yet used (CCB or diuretic) 3

Special Population Considerations

• Initial therapy for Black patients with CKD should include a thiazide-type diuretic or calcium channel blocker, either alone or in combination with an ACE inhibitor/ARB 2, 3
• Use a dihydropyridine calcium channel blocker as first-line therapy for kidney transplant recipients, as this improves GFR and kidney survival in transplant patients 1, 3
• Apply the same BP targets and medication choices as younger patients for elderly patients (>80 years), provided treatment is well tolerated 3

Critical Contraindications and Precautions

• Never combine an ACE inhibitor, ARB, and direct renin inhibitor together in CKD patients—this increases adverse events without additional benefit 1, 2, 3
• ACE inhibitors and ARBs are absolutely contraindicated during pregnancy 3
• Use caution with ACE inhibitors/ARBs in patients with peripheral vascular disease due to association with renovascular disease 3

Managing Hyperkalemia

• Hyperkalemia associated with ACE inhibitor/ARB use can often be managed with measures to reduce serum potassium rather than stopping the renin-angiotensin system blocker 3

Common Pitfalls to Avoid

• Inadequate diuretic dosing leads to fluid retention and poor BP control, while excessive dosing causes volume contraction, hypotension, and worsening renal function 2, 3
• Do not discontinue antihypertensive medications simply because BP falls below target if the patient tolerates the regimen without adverse effects—continue the effective therapy 4, 5

Optimal Management of Uncontrolled Hypertension in CKD Stage 3b

Blood Pressure Target

• The American College of Cardiology and Kidney Disease: Improving Global Outcomes (KDIGO) recommend targeting systolic BP <120 mmHg using standardized office measurement for cardiovascular and survival benefits in patients with CKD Stage 3b and hypertension, though this more aggressive target is based primarily on SPRINT trial data 6, 7
• The target BP should be <130/80 mmHg for patients with CKD Stage 3b (eGFR 56) and hypertension, as recommended by the Kidney International and Annals of Internal Medicine 7, 8

Medication Optimization Strategy

• The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend maximizing ACE inhibitor dose to the highest approved dose that is tolerated to achieve maximum renoprotective benefits in patients with CKD Stage 3b and hypertension 6, 7
• The American Heart Association recommends adding a thiazide-like diuretic, such as chlorthalidone 12.5-25 mg daily or hydrochlorothiazide 25 mg daily, if BP remains >130/80 mmHg after maximizing ACE inhibitor dose in patients with CKD Stage 3b and hypertension 9, 10
• The American College of Cardiology recommends considering discontinuing or reducing beta-blocker dose once BP is controlled with optimized ACE inhibitor, diuretic, and calcium channel blocker in patients with CKD Stage 3b and hypertension, as beta-blockers are not first-line agents for hypertension in CKD unless there are compelling indications 9, 10

Monitoring Protocol

• The Annals of Internal Medicine recommends checking BP, serum creatinine, and potassium 2-4 weeks after each medication adjustment in patients with CKD Stage 3b and hypertension, and reassessing BP monthly until target <130/80 mmHg is achieved, then monitoring every 2-4 months 8

Evidence Strength and Nuances

• The recommendation to maximize ACE inhibitor dosing is strongly supported by the 2021 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines, which emphasize that ACE inhibitors reduce both cardiovascular events and kidney disease progression in CKD patients 6, 7
• The BP target of <130/80 mmHg represents a consensus between the 2017 American College of Cardiology/American Heart Association (ACC/AHA) guidelines and practical clinical application, as the more aggressive <120 mmHg target from KDIGO is based primarily on standardized office measurements and may not be achievable in all patients 7, 8

Antihypertensive Management in Chronic Kidney Disease

First‑Line Therapy Selection

• For adults with chronic kidney disease (CKD) who are at stage 3 or higher, or who have albuminuria ≥ 300 mg/day, ACE inhibitors are the preferred first‑line antihypertensive agents. 11, 12
• In patients with CKD stage 3 or higher, regardless of albuminuria status, initiate ACE‑inhibitor therapy as the first‑line treatment. 11, 12
• In patients with CKD stage 1‑2 who have albuminuria ≥ 300 mg/day, start an ACE inhibitor as first‑line therapy. 11, 12
• In patients with CKD stage 1‑2 without significant albuminuria, standard first‑line antihypertensive options (thiazide diuretics, calcium‑channel blockers, ACE inhibitors, or ARBs) may be used. 11

Blood Pressure Targets

• The blood‑pressure goal for all adults with CKD and hypertension is < 130/80 mmHg. 11, 12

Alternative Therapy When ACE Inhibitor Intolerant

• If an ACE inhibitor cannot be tolerated, switch to an angiotensin‑receptor blocker (ARB); ARBs provide comparable renoprotective benefits. 11, 12

Special Populations

• For kidney‑transplant recipients, a dihydropyridine calcium‑channel blocker is recommended as first‑line therapy because it improves glomerular filtration rate and graft survival. 11, 12
• In patients receiving mTORC1 inhibitors, the risk of angioedema with ACE inhibitors is increased; an ARB should be considered the preferred first‑line agent. 13